Dr.POOJA KHAMAR

Prof.ROHIT SHETTY

Abstract

Purpose: To evaluate the role of personalized Ocular surface disease(OSD) Management with tear biomarkers using a lab on chip. Methods: 3,500 OSD eyes(DED and KC) and 7,500 controls were recruited. Selected biomarkers in tears (MMP-9, IL-6, IL-1b, I-CAM-1, IL-10a, IL-17a, TNF-a, VEGF-a) were analyzed using a lab on chip. Based on normative database, targeted therapy was instituted and reassessed at 6 months.Results: 60% eyes had high MMP-9, of which 30% had 3-fold rise compared to controls. Eyes with single-fold rise received immunomodulators. Those with > 2-fold rise, received vector pulsation+ IPL therapy and immunomodulators. 10% had high ICAM-1, treated with lifitegrast. 20% had high TNF-a and IL-17a, treated with steroids and lubricants. Post-treatment eyes had reduced symptoms, signs, targeted biomarkers, drug response time and treatment failure rate.Conclusion: Biomarkers enabled personalized OSD management will herald a paradigm shift with a potential to reduce the cost burden.

Full Text